Home
/
Caribou Biosciences, Inc.
/
Financials
/
Quarterly
Caribou Biosciences, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Caribou Biosciences, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2021
Jun 30, 2021
$0
Sep 2, 2021
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$2.20M
Nov 12, 2025
Q2
2025
Jun 30, 2025
$2.67M
Aug 12, 2025
Q1
2025
Mar 31, 2025
$2.35M
May 8, 2025
Q3
2025
Sep 30, 2024
$2.02M
Nov 12, 2025
Q2
2025
Jun 30, 2024
$3.46M
Aug 12, 2025
Q1
2025
Mar 31, 2024
$2.43M
May 8, 2025
Q3
2024
Sep 30, 2023
$23.66M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$3.76M
Aug 6, 2024
Q1
2024
Mar 31, 2023
$3.50M
May 7, 2024
Q3
2023
Sep 30, 2022
$3.30M
Nov 7, 2023
Q2
2023
Jun 30, 2022
$4.19M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$2.66M
May 9, 2023
Q3
2022
Sep 30, 2021
$3.98M
Nov 8, 2022
Q2
2022
Jun 30, 2021
$1.48M
Aug 9, 2022
Q1
2022
Mar 31, 2021
$1.59M
May 9, 2022
Q3
2021
Sep 30, 2020
$1.20M
Nov 9, 2021
Q2
2021
Jun 30, 2020
$8.48M
Sep 2, 2021
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($27.55M)
Nov 12, 2025
Q3
2025
Jun 30, 2025
($54.10M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($54.10M)
Aug 12, 2025
Q2
2025
Mar 31, 2025
($39.99M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($39.99M)
May 8, 2025
Q3
2025
Mar 31, 2025
($39.99M)
Nov 12, 2025
Q3
2025
Sep 30, 2024
($34.68M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($37.70M)
Aug 12, 2025
Q3
2025
Jun 30, 2024
($37.70M)
Nov 12, 2025
Q2
2025
Mar 31, 2024
($41.23M)
Aug 12, 2025
Q3
2025
Mar 31, 2024
($41.23M)
Nov 12, 2025
Q1
2025
Mar 31, 2024
($41.23M)
May 8, 2025
Q3
2024
Sep 30, 2023
($10.00M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($29.52M)
Aug 6, 2024
Q3
2024
Jun 30, 2023
($29.52M)
Nov 6, 2024
Q3
2024
Mar 31, 2023
($28.04M)
Nov 6, 2024
Q1
2024
Mar 31, 2023
($28.04M)
May 7, 2024
Q2
2024
Mar 31, 2023
($28.04M)
Aug 6, 2024
Q3
2023
Sep 30, 2022
($26.65M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($26.70M)
Aug 8, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($29.40M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($47.58M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($42.91M)
May 8, 2025
Q3
2025
Sep 30, 2024
($38.24M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($43.50M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($46.00M)
May 8, 2025
Q3
2024
Sep 30, 2023
($14.63M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($32.87M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($31.12M)
May 7, 2024
Q3
2023
Sep 30, 2022
($26.54M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($28.43M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($20.85M)
May 9, 2023
Q3
2022
Sep 30, 2021
($18.62M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($15.96M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($13.18M)
May 9, 2022
Q3
2021
Sep 30, 2020
($8.23M)
Nov 9, 2021
Q2
2021
Jun 30, 2020
($2.26M)
Sep 2, 2021